このページの翻訳は実験的なもので、現在開発中です。お待ちしております
EyePoint Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /66
EyePoint Pharmaceuticalsの総株主資本は$228.3M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$324.2Mと$95.9Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$280.25m |
| エクイティ | US$228.31m |
| 負債合計 | US$95.94m |
| 総資産 | US$324.25m |
財務の健全性に関する最新情報
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Recent updates
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02財務状況分析
短期負債: EYPTの 短期資産 ( $294.9M ) が 短期負債 ( $62.1M ) を超えています。
長期負債: EYPTの短期資産 ( $294.9M ) が 長期負債 ( $33.8M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: EYPTは負債がありません。
負債の削減: EYPT負債比率が163.9%であった 5 年前と比べて負債がありません。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: EYPTは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。
キャッシュランウェイの予測: EYPTは、フリー キャッシュ フローが毎年5.5 % の歴史的成長率で成長し続ける場合、 2.3年間十分なキャッシュ ランウェイを有します。